Li Ding, PhD

Li Ding, PhD

Primary Academic Title

Professor of Medicine, Division of Oncology, Section of Stem Cell Biology, Washington University School of Medicine

Research Interest

Identifying and characterizing somatic/germline genetic changes relevant to cancer initiation and progression as well as drug response by integrating various data types, including DNA, RNA and proteomics data. Developing algorithms to facilitate the translation of genomic findings to clinical practice.

Education

  • 1998: PhD, biochemistry, University of Utah, Salt Lake City

Training

  • 1998 - 2999: Postdoctoral fellow, biochemistry, Stanford University, Palo Alto, Calif.

Selected Research Publications

Epigenetic regulation during cancer transitions across 11 tumour types.
  • Terekhanova NV, Karpova A, Liang WW, [...] Ding L
  • Nature 2023
Deep learning integrates histopathology and proteogenomics at a pan-cancer level.
  • Wang JM, Hong R, Demicco EG, [...] Ding L, [...] Fenyö D
  • Cell Rep Med 2023
Fibrosis induced by resident macrophages has divergent roles in pancreas inflammatory injury and PDAC.
  • Baer JM, Zuo C, Kang LI, [...] Ding L, [...] DeNardo DG
  • Nat Immunol 2023
Pan-cancer proteogenomics connects oncogenic drivers to functional states.
  • Li Y, Porta-Pardo E, Tokheim C, [...] Ding L
  • Cell 2023
Single-nucleotide variant calling in single-cell sequencing data with Monopogen.
  • Dou J, Tan Y, Kock KH, [...] Ding L, [...] Chen K
  • Nat Biotechnol 2023
Proteogenomic data and resources for pan-cancer analysis.
  • Li Y, Dou Y, Da Veiga Leprevost F, [...] Ding L, [...] Payne SH
  • Cancer Cell 2023
Pharmaco-proteogenomic characterization of liver cancer organoids for precision oncology.
  • Ji S, Feng L, Fu Z, [...] Ding L, [...] Gao Q
  • Sci Transl Med 2023

View All Publications